RAPT Therapeutics, Inc. (RAPT)
Mar 3, 2026 - RAPT was delisted (reason: acquired by GSK)
58.02
0.00 (0.00%)
Inactive · Last trade price on Mar 2, 2026
RAPT Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 37.93 | 169.74 | 47.48 | 38.95 | 24.03 | 24.92 |
Short-Term Investments | 119.41 | 61.32 | 111.38 | 210.12 | 165.63 | 86.59 |
Cash & Short-Term Investments | 157.34 | 231.06 | 158.86 | 249.07 | 189.65 | 111.51 |
Cash Growth | 60.71% | 45.44% | -36.22% | 31.33% | 70.08% | 44.10% |
Prepaid Expenses | 3.7 | 4.18 | 2.92 | 3.63 | 3.32 | 4.09 |
Total Current Assets | 161.05 | 235.24 | 161.78 | 252.69 | 192.97 | 115.6 |
Property, Plant & Equipment | 2.65 | 4.7 | 7.68 | 9.48 | 2.74 | 2.98 |
Other Long-Term Assets | 2.05 | 0.39 | 3.87 | 4.04 | 2.92 | 0.39 |
Total Assets | 165.74 | 240.33 | 173.33 | 266.21 | 198.64 | 118.97 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 2.1 | 1.28 | 5.18 | 3.37 | 2 | 2.38 |
Accrued Expenses | 9.01 | 44.6 | 14.1 | 8.66 | 6.33 | 4.94 |
Current Portion of Leases | 2.21 | 2.42 | 2.45 | 2.17 | - | - |
Current Unearned Revenue | - | - | - | - | 1.02 | 4.1 |
Other Current Liabilities | 0.06 | 0.06 | 0.11 | 0.03 | 0.25 | 0.33 |
Total Current Liabilities | 13.38 | 48.35 | 21.84 | 14.22 | 9.6 | 11.74 |
Long-Term Leases | 0.39 | 2.07 | 4.46 | 6.82 | - | - |
Long-Term Unearned Revenue | - | - | - | - | 0.51 | 0.86 |
Other Long-Term Liabilities | - | - | - | - | 2.15 | 2.19 |
Total Liabilities | 13.76 | 50.42 | 26.29 | 21.04 | 12.26 | 14.79 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | 0.01 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 818.81 | 804.39 | 631.61 | 613.07 | 470.63 | 319.2 |
Retained Earnings | -666.94 | -614.55 | -484.68 | -367.88 | -284.05 | -214.84 |
Comprehensive Income & Other | 0.1 | 0.05 | 0.1 | -0.03 | -0.21 | -0.18 |
Total Common Equity | 151.98 | 189.9 | 147.04 | 245.17 | 186.38 | 104.18 |
Shareholders' Equity | 151.98 | 189.9 | 147.04 | 245.17 | 186.38 | 104.18 |
Total Liabilities & Equity | 165.74 | 240.33 | 173.33 | 266.21 | 198.64 | 118.97 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 2.6 | 4.49 | 6.91 | 8.99 | - | - |
Net Cash (Debt) | 154.75 | 226.56 | 151.96 | 240.08 | 189.65 | 111.51 |
Net Cash Growth | 66.78% | 49.10% | -36.71% | 26.59% | 70.08% | 44.10% |
Net Cash Per Share | 7.14 | 44.47 | 31.71 | 59.02 | 55.39 | 36.96 |
Filing Date Shares Outstanding | 27.71 | 16.5 | 4.35 | 4.29 | 3.7 | 3.11 |
Total Common Shares Outstanding | 16.86 | 16.5 | 4.3 | 4.28 | 3.69 | 3.1 |
Working Capital | 147.67 | 186.89 | 139.95 | 238.47 | 183.38 | 103.86 |
Book Value Per Share | 9.02 | 11.51 | 34.20 | 57.26 | 50.45 | 33.64 |
Tangible Book Value | 151.98 | 189.9 | 147.04 | 245.17 | 186.38 | 104.18 |
Tangible Book Value Per Share | 9.02 | 11.51 | 34.20 | 57.26 | 50.45 | 33.64 |
Machinery | 7.85 | 8.15 | 8.52 | 7.49 | 7.13 | 6.77 |
Leasehold Improvements | 3.3 | 3.3 | 3.3 | 3.3 | 3.3 | 3.29 |